Rouxinol-Dias Ana Lídia, Pinto Ana Raquel, Janeiro Catarina, Rodrigues Daniel, Moreira Marta, Dias João, Pereira Pedro
Center for Research in Health Technologies and Information Systems (CINTESIS), Faculty of Medicine, University of Porto, Porto, Portugal.
2 Laboratory of Immunology, Basic and Clinical Immunology Unit, Faculty of Medicine, University of Porto, Porto, Portugal.
Porto Biomed J. 2016 Mar-Apr;1(1):12-24. doi: 10.1016/j.pbj.2016.03.005. Epub 2016 Mar 1.
Obesity is a growing epidemic worldwide. Evidence so far demonstrates that the bacteria that are commonly found in the human gastrointestinal tract affect nutrient acquisition and energy regulation. This suggests that an important role is played by gut microbiota in the development of obesity.
Our main goal was to assess if a probiotic diet leads to a significant difference in weight change in non-obese and obese people, and in experimental models.
Search was undertaken in PubMed, Scopus, ISI Web of knowledge, Cochrane Central Register of Controlled Trials, Google scholar, meta-Register of Controlled Trials, ClinicalTrials.gov and by scanning reference lists of articles, without publication date imposed, for randomised clinical trials studying the administration of probiotics to obese or overweight patients and experimental studies in experimental models and healthy humans. Search terms included probiotics, obesity, weight, BMI, weight gain, weight loss, weight change, probiotic diet and probiotic therapy. In an unblended standardized manner, 2 reviewers analysed the searched studies, using the defined inclusion and exclusion criteria, and performed extraction of data, in an independent way, using predefined data fields.
We've identified, through searching databases specified in methods, 269 records. A total of 4 clinical trials and 14 experimental studies were included in the systematic review. Among the 4 randomized clinical trials only one showed statistically significant results. CGMCC 1.3724 was efficient in reducing weight in females, but not in males - Mean weight loss 12 week/24 week (kg): Males-probiotic: 4/5.4; Males-placebo: 3.05/4.43; Females-probiotic: 4.4/5.2; Females- placebo: 2.6/2.5 (P<0.05 only on females).
In our systematic review, we found that probiotic effect in body weight is specie and strain specific. BNR17, reduced the weight gain compared to controls; L66-5 promoted weight gain, GGMCC is the only one that had a positive effect in weight loss in humans. Probiotic effect in body weight was species and strain specific. On the other hand LG42, SBT2055 and co-therapy with KY103 and HY7601 had an anti-obesity effect in animal models.
肥胖在全球范围内呈日益流行之势。目前的证据表明，人类胃肠道中常见的细菌会影响营养获取和能量调节。这表明肠道微生物群在肥胖的发生发展中起着重要作用。
我们的主要目标是评估益生菌饮食是否会使非肥胖和肥胖人群以及实验模型中的体重变化产生显著差异。
在PubMed、Scopus、ISI Web of knowledge、Cochrane对照试验中央注册库、谷歌学术、对照试验元注册库、ClinicalTrials.gov中进行检索，并通过浏览文章的参考文献列表（不设发表日期限制），以查找研究向肥胖或超重患者施用益生菌的随机临床试验以及在实验模型和健康人类中的实验研究。检索词包括益生菌、肥胖、体重、体重指数、体重增加、体重减轻、体重变化、益生菌饮食和益生菌疗法。由2名评审员以统一的标准化方式，使用既定的纳入和排除标准对检索到的研究进行分析，并独立使用预定义的数据字段进行数据提取。
通过在方法中指定的数据库检索，我们识别出269条记录。系统评价共纳入4项临床试验和14项实验研究。在4项随机临床试验中，只有1项显示出具有统计学意义的结果。CGMCC 1.3724对女性体重减轻有效，但对男性无效——12周/24周平均体重减轻（千克）：男性-益生菌组：4/5.4；男性-安慰剂组：3.05/4.43；女性-益生菌组：4.4/5.2；女性-安慰剂组：2.6/2.5（仅女性P<0.05）。
在我们的系统评价中，我们发现益生菌对体重的影响具有物种和菌株特异性。与对照组相比，BNR17减轻了体重增加；L66-5促进了体重增加，GGMCC是唯一对人类体重减轻有积极作用的菌株。益生菌对体重的影响具有物种和菌株特异性。另一方面，LG42、SBT2055以及与KY103和HY7601联合治疗在动物模型中具有抗肥胖作用。
